Nascent biotechnology firm Solidus Biosciences is developing a cell-based assay chip that it says can perform rapid and inexpensive assessment of ADME/tox early on in the drug-development process, thereby eliminating unsuitable small-molecule candidates from further investigation.

The technology, which has been dubbed MetaChip, combines an array of sol-gel encapsulated cytochrome P450 metabolizing enzymes with a monolayer of cells on a micro-scale glass slide that can be read using any standard microarray scanner, fluorescent microscope, or combination thereof.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.